Skowronek J, Adamska K, Filipiak K, Karaś Z, Krenz R M, Rutkowski R, Warchoł J B
Great Poland Cancer Center, Department of Radiotherapy, Poznań, Poland.
Neoplasma. 1997;44(5):282-8.
The determination of DNA content in human cancers is the subject of increasing interest, particularly in view of its potential clinical applications. There are relatively few studies which describe DNA content of skin neoplasms and pigmented nevi. These studies have shown conflicting results. In the present investigation the authors measured DNA ploidy using flow and video-imaging cytometry in 51 malignant melanomas, 20 skin cancers and 48 pigmented nevi. For DNA measurement paraffin embedded tissues and fresh cell smears were used. Clinical and histological data of malignant melanomas were recorded and correlated with DNA ploidy. DNA histograms were examined for DNA aneuploidy by DNA Index. DNA ploidy in primary lesions of melanomas and their metastases were compared. The aneuploidy rate, found in our observation, was significantly higher in whole malignant melanoma group, in clinical Stage II and III, in tumors with thickness greater then 1.5 mm, tumors with Clark level III, IV and V. Another clinical and histological factors did not show significant correlation with ploidy. Aneuploidy was found in 8 of 20 (45.0%) skin cancers. In the whole population of pigmented nevi aneuploid DNA content was identified in 10 nevi (20.1%). The results of this study suggest that aneuploidy seems to be connected with advanced stage of malignant melanoma but it does not replace other prognostic factors. Both cytometric methods can be used for routine DNA ploidy analysis. Ploidy studies are not useful for predicting metastatic potential of primary melanoma. Results obtained from fresh cell smears and paraffin embedded tissues were identical.
人类癌症中DNA含量的测定越来越受到关注，特别是鉴于其潜在的临床应用价值。描述皮肤肿瘤和色素痣DNA含量的研究相对较少。这些研究结果相互矛盾。在本研究中，作者使用流式细胞术和视频成像细胞术测量了51例恶性黑色素瘤、20例皮肤癌和48例色素痣的DNA倍性。DNA测量使用石蜡包埋组织和新鲜细胞涂片。记录恶性黑色素瘤的临床和组织学数据，并与DNA倍性相关联。通过DNA指数检查DNA直方图以检测DNA非整倍体。比较黑色素瘤原发灶及其转移灶的DNA倍性。在我们的观察中，整个恶性黑色素瘤组、临床II期和III期、厚度大于1.5mm的肿瘤、Clark分级为III、IV和V级的肿瘤中，非整倍体率显著更高。其他临床和组织学因素与倍性未显示出显著相关性。20例皮肤癌中有8例（45.0%）发现非整倍体。在整个色素痣群体中，10例痣（20.1%）鉴定出非整倍体DNA含量。本研究结果表明，非整倍体似乎与恶性黑色素瘤的晚期有关，但它并不能替代其他预后因素。两种细胞计数方法均可用于常规DNA倍性分析。倍性研究对预测原发性黑色素瘤的转移潜能无用。从新鲜细胞涂片和石蜡包埋组织获得的结果相同。
